Skip to main content
OpenTrials
Completed

NCT Number: NCT01309139

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

The primary objective is to compare the systemic exposure to tiotropium and CD 1857 after treatment with the fixed dose combination (fixed dose combination (FDC), Treatment A) of tiotropium plus BI 54903 (ethanolic solution for inhalation (EIS), Respimat (RMT) B) with the systemic exposure following inhalation of the free combination (Treatment B) of tiotropium (aqueous solution for inhalation (AIS), RMT A) plus BI 54903 (EIS, RMT B), when administered once-daily over 21 days via Respimat(R) (RMT).

The secondary objectives are:

to compare the systemic exposure to tiotropium and CD 1857 after single dose administration of FDC and of the free combination of tiotropium/BI 54903 to compare the systemic exposure to BI 54903 after a single dose and at steady state after multiple doses of the FDC and of the free combination of tiotropium/BI 54903 to compare the safety and tolerability of tiotropium and BI 54903 when administered as FDC and as free dose combination, respectively

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

1298.2.1 Boehringer Ingelheim Investigational Site

Ingelheim, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests.
  • Age 21 to 50 years.

Exclusion criteria

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • History or evidence of relevant psychiatric disorders or neurological disorders
  • History or evidence of relevant autonomic dysfunction (orthostatic hypotension, fainting spells or blackouts)
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  • Intake of any prescription drugs or over-the-counter (over the counter (OTC)) medication (vitamins, herbal supplements, dietary supplements) with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (more than 10 cigarettes daily)

Treatment and study plan

Tiotropium

Drug

Medium dose of oral inhalation

BI 54903

Drug

Medium dose of oral inhalation

Primary outcomes

  1. Area under the concentration time curve of CD 1857 in plasma over a uniform dosing interval τ (AUCτ,ss)

    Time frame: on several time points until day 22

  2. Maximum concentration of CD 1857 in plasma at steady state (Cmax,ss)

    Time frame: on several time points until day 22

  3. AUCτ,ss for Tiotropium

    Time frame: on several time points until day 22

  4. Cmax,ss for Tiotropium

    Time frame: on several time points until day 22

Secondary outcomes

  1. AUCτ,ss for BI 54903

    Time frame: on several time points until day 22

  2. Cmax,ss for BI 54903

    Time frame: on several time points until day 22

  3. Ae0-24 (Amount of analyte that is eliminated in urine) for tiotropium

    Time frame: on Day 1 and 21

  4. Change in physical examination

    Time frame: 9 weeks

  5. Change in vital signs

    Time frame: 9 weeks

  6. Change in 12-lead electrocardiogram

    Time frame: 9 weeks

  7. Change in clinical laboratory tests

    Time frame: 9 weeks

  8. Occurrence of Adverse Events

    Time frame: 9 weeks

  9. Assessment of tolerability by the investigator

    Time frame: 9 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat® B Versus the Combination of the Monoproducts of Tiotropium Via Respimat® A and BI 54903 Via Respimat® B in Healthy Volunteers

Important dates

Study start
2011
Primary completion
2011
First posted
Mar 4, 2011
Registry last updated
Nov 1, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.